A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.

Compositions may include a therapeutic that is released from the composition to treat any number of ailments or conditions (e.g., pain, infection, cancer, osteoporosis) or to help accelerate local tissue regeneration (e.g., growth hormone, bone morphogenic protein) or to assist with surgical or therapeutic treatment (e.g., imaging modality), or any of a combination thereof.

The particle (1) is suitable for the manufacture of an implantable soft tissue engineering material and comprises: a three-dimensionally warped and branched sheet (2) where (i) the three-dimensionally warped and branched sheet (2) is made from a biocompatible material having a Young's modulus of 1 kPa to 1 GPa; (ii) the three-dimensionally warped and branched sheet (2) has an irregular shape which is encompassed in a virtual three-dimensional envelope (3) having a volume V.sub.E; (iii) the three-dimensionally warped and branched sheet (2) has a mean sheet thickness T; iv) the three-dimensionally warped and branched sheet (2) has a volume V.sub.S; (v) the particle (1) has a Young's modulus of 100 Pa to 15 kPa; and (vi) the particle (1) further comprises a number of protrusions where the three-dimensionally warped and branched sheet (2) reaches the envelope (3); (vii) the particle (1) has a number of interconnected channel-type conduits (5) defined by the branching of the sheet (2) and/or by voids in the sheet (2); and (viii) where the conduits (5) have (a) a mean diameter D.sub.C; and (b) an anisotropicity index of 1.01 to 5.00.

Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.

The present disclosure generally relates to a process for manufacturing a microparticle composite or a dry powder inhaler composition of polymyxin and CFTR activator or CFTR potentiator comprising the steps preparing a suspension of nanoparticles (NPs) of CFTR activator or CFTR potentiator or their combinations; mixing the suspension of NPs with a solution of polymyxin and a solution of leucine, then followed by drying to afford said micro-particle composite or dry powder inhaler composition. Pharmaceutical compositions and methods for treating a patient of cystic fibrosis (CF) and/or a lung infection are within the scope of this invention.

Provided herein are compounds, compositions and method of using thereof to treat or prevent malaria.

A process for preparing a powder for reconstitution as a suspension includes the following steps: First, complexing Valaciclovir with an ion exchange resin and forming Drug-Resin complex (DRC) particles. The complexing includes Dry blending of Drug:Ion Exchange Resin in a ratio 1:0.8 to form a blend; Kneading the blend with water in a ratio of Drug:Ion Exchange Resin:Water 1:0.8:0.5 to form a wet mass; Drying of the wet mass at 40° C.
Next, milling of the Drug-Resin complex particles until particle size gets less than 250 μm, and then dry mixing of the Drug-Resin complex particles with excipients to form an internal phase. The excipients of the internal phase comprise a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. Next, mixing the internal phase with excipients of an external phase to form the powder, and then sifting the powder to eliminate any clumps.

Pharmaceutical compositions and stable nano-suspensions comprising mifepristone and at least one pharmaceutically acceptable excipient, which exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. Manufacturing process and methods of use are also provided. The pharmaceutical compositions are used for prevention, treatment or prophylaxis of disorders in human patients in need thereof. Oral pharmaceutical compositions of mifepristone, methods for their administration, processes for thei r production, and use of these compositions are described for the treatment of diseases for which mifepristone is indicated.

Hot-melt extrusion for producing solid solution comprising nanoparticle formulation of decoquinate is disclosed. Aqueous phase comprising the nanoparticles of hot-melt extruding products is homogeneous and stable. Provided is the composition comprising the solid solution of decoquinate and a method of hot-melt extrusion for producing this composition comprising the solid dispersion of decoquinate. Furthermore, provided is the solid solution comprising nanosized decoquinate formulation having improved water solubility and enhanced delivery of decoquinate in digestive system for absorption, increasing bioavailability, and the efficacy against malaria at the liver stage.

Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.